Roche shares pop 4% on $5.3 billion obesity drug deal with Zealand Pharma

Roche has agreed to a $5.3 billion deal with Zealand Pharma to develop the obesity drug candidate petrelintide, including a fixed-dose combination with Roche’s CT-388, aiming to compete in the weight loss drug market. Zealand Pharma will receive $1.65 billion upfront and potential milestone payments, with shares of both companies rising after the announcement. The partnership will see Roche and Zealand jointly commercialize petrelintide in the U.S. and Europe, sharing profits and losses equally, while Roche will have exclusive commercialization rights in the rest of the world.

Full Article